Molecular Formula | C25H27N3O5 |
Molar Mass | 449.5 |
Density | 1.332±0.06 g/cm3(Predicted) |
Boling Point | 717.8±60.0 °C(Predicted) |
Solubility | DMSO: ≥30 mg/mL |
pKa | 10.70±0.40(Predicted) |
Storage Condition | -20℃ |
In vitro study | In cell degradation experiments, treatment with CC-220 resulted in the disappearance of Ikaros protein with an EC50 of 1 nM. CC-220 is equally effective for Aiolos, with an EC50 of 0.5 nM. CC-220 is a potent anti-proliferative, pro-apoptotic compound with activity against a variety of MM cell lines. CC-220 induced PBMC-mediated killing activity in multiple myeloma cells, regardless of the level of cereblon expression and cellular autonomic sensitivity. CC-220 can act by binding to cereblon, leading to degradation of the hematopoietic transcription factors Ikaros and Aiolos, and disruption of the MM-promoted c-Myc/IRF4 axis. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.225 ml | 11.123 ml | 22.247 ml |
5 mM | 0.445 ml | 2.225 ml | 4.449 ml |
10 mM | 0.222 ml | 1.112 ml | 2.225 ml |
5 mM | 0.044 ml | 0.222 ml | 0.445 ml |
biological activity | Iberdomide (CC-220) is a novel oral immunomodulatory compound, targeting cereblon(cereblon is part of the CRL4 CRBN E3 ubiquitin ligase complex) with an IC50 of 60 nM. Iberdomide (CC-220) induces apoptosis and has antitumor and Immunostimulatory activity. |
Target | Value |
cereblon () | 60 nM |